top of page


HBS Alumni Angels syndicates selected deals across the full global membership of its 14 chapters. This enables selected deals from one chapter to reach a global network of accredited investor alumni. This is a unique benefit of being a member in a local HBS Alumni Angel chapter. Investment decisions are made and executed individually following a global webinar. Once investments are made, investors often assist companies in other areas as formal or informal advisers. For details on how the process works, please scroll down.


20240229 WURQ Logo1.png


Thursday, February 29, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Dmitry Popov, CEO & Co-Founder of WURQ
Complimentary for HBS Angels Members


On behalf of the Washington DC chapter, we would like to share the following investment opportunity:

Harvard's direct ownership in WurQ results from a technology transfer, with collaborative intellectual property contributing to the company's establishment. This partnership between academia and entrepreneurship is reinforced by valuable support from the National Science Foundation and the NFL Players Health Study during the startup's research phase, enhancing its foundation for innovation. Today, our team addresses automation challenges in tracking physical work, assessing its amount, intensity, and quality. As an AI and software company, we utilize off-the-shelf wearables to visualize progression, enable gamification, and provide guidance at scale. We believe our efforts will bring efficiency and safety to the industries of sports, healthcare, and workforce.

The Opportunity

By 2040, streams of health data will merge to create a highly personalized picture of every consumer's well-being. Currently, we monitor calories consumed, hours slept, steps walked, etc. The number of wearables worldwide has increased significantly, from 325 million in 2016 to 722 million in 2019. While there are numerous solutions for monitoring cardio health, there is a gap in muscle health data. Monitoring strength training is challenging in practice, yet it represents a critical opportunity. Over 185 million people globally participate in strength training. CDC data indicates that strength training is the second most popular form of exercise in the US, with 76 million people meeting the recommended standards. Its importance is recognized by wellness businesses, who are in search of scalable tools to enhance accountability, personalization, and performance assessment.


The Solution

WurQ is a software platform that leverages existing wearables (Apple, Garmin, etc.) to automate workout logging during strength training. Our AI-driven system utilizes the motion sensors from these wearables. With a single smartwatch, WurQ can recognize common training movements (like bench presses, bicep curls) and time spent doing those. By using two wearables, a smartwatch and a chest strap, WurQ can recognize a wide range of movements (including box jumps, pull-ups, push-ups, etc.), count reps and sets, monitor form, assess strength levels, recommend weights, measure active versus rest time, and more. This technology can integrate via SDKs and APIs into existing businesses in fitness, healthcare, and tactical sectors. Imagine the following possibilities in the near future:

  • You walk into a gym, connect your smartwatch to the gym's app, and start your training session.

  • Every exercise is automatically logged into your training history. Meanwhile, the gym owner gains insights into how the gym equipment is utilized and shares simple guidance to improve your training.

  • As you begin to see the value, you go to the front desk to get a chest strap to wear during your workouts.

  • With two sensors, you now receive assessments of your exercise form, recommendations on the appropriate weight to use for efficient training, workload management to prevent injury, and a visualization of your strength level. Meanwhile, the gym owner can tailor your training plan and conduct monthly assessments.



While our vision is to partner with the broader fitness and healthcare ecosystem, we are initially focusing on the CrossFit community. This decision was driven by the willingness of end users to test an early MVP, their high disposable incomes (+$150k/yr), and the lack of meaningful tracking solutions in this space. We've presold 150 systems directly to consumers to validate demand, conducted a 3-month trial in 6 local gyms with hundreds of athletes, and are now in the process of finalizing our first partnership with a major CrossFit provider. The pilot for this partnership is scheduled for mid-March 2024, with a product launch planned for July 2024.


Market Opportunity

Initial market, CrossFit: $1.5B TAM (all users), $621M SAM (40% of Top competitive & Ex-Athletes), $124M SOM (8%, CrossFit has a high adoption rate).

Total market: $55B TAM (gym goers, athletes, personal trainers), $11B SAM (20% of the total target), $550M SOM (5% share of the serviceable market)


Business Model

Our initial model is B2B2C, where a fitness provider utilizes WurQ's white-label app to track users' progress and drive retention and personalization. WurQ manages the app and assists an existing fitness brand in marketing and distributing the product to its committed audience, who pays a $24 monthly subscription. WurQ offers 30% revenue share to the fitness provider. In the long term, as we gain the capability to integrate into existing providers' apps, we will transition to a pure B2B, SaaS model.



WurQ is raising $300K on a convertible note, aiming to close the round by April 2024. This capital enables us to complete the first pilot with the fitness provider and initiate the product launch, while supporting the company's operations until September 2024. To date, WurQ has raised $1.2M on a convertible note with a $5M cap and $400K with an $8M cap and has received a grant of $250K from the NSF.



Industry: Technology (AI, SaaS) and Wellness

Founded: Dec 2021


$300K, Pre-Seed

$8M Cap, 5% interest, 20% discount.


Kiplin Capital, Launchpad Venture Group, Benjamin Griswold IV (HBS alumni), Paul Mandell (CEO at Consero Group), Akash Magoon (CEO at Adonis & Nayya), Pete Iacobelli (CEO at 910 Media Group), and others.




20240229 WURQ Popov 200X.jpg



Dmitry Popov, PhD is a Co-Founder and CEO at WurQ. He earned his Ph.D. in mechanical engineering from Korea University of Technology, where he also pursued post-doctoral research focusing on wearable assistive technologies and has founded his first technology startup in the automative space. Dmitry continued his post-doctoral research with the Harvard Biodesign Lab, utilizing bio-inspired robotics techniques. He was part of the winning team in the DARPA exosuit challenge and has developed assistive solutions, such as a soft brace designed to protect athletes against ACL injuries. He was a Technology Development Fellow at the Wyss Institute for Biologically Inspired Engineering, where he led a project team to build upon prior research on wearable tech and bring WurQ to market. Dmitry’s passion for sport underpins his work, and his inspiration comes from a desire to bring the community and progress visualization of cardio to the strength training sphere.

ZOOM Meeting information will be included in your registration receipt.

Please check spam/bulk/junk folders if you don't see it.


20221117 Agile Devices HIRES_edited.jpg


Thursday, March 14, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Ben Merewitz, CEO & Co-Founder of Agile Devices
Complimentary for HBS Angels Members


Agile Devices is a medical device company dedicated to the invention and realization of innovative catheter technologies designed to reduce procedure time, cost, and risk. With a focus on interventional radiology, cardiology and neuroradiology, Agile Devices seeks to deliver these technologies to the marketplace, thus benefiting patients, doctors, and hospitals in the US and around the world.

Agile Devices ( has developed a novel catheter technology designed to reduce interventional procedure time, cost, and risk. Our platform technology features a patented coaxial design for bi-directional deflection without the need for pullwires.
Our flagship product, the Angler® Steerable and Deflectable Microcatheter, was recently FDA-cleared for peripheral and coronary vascular interventions, and subsequently used in a limited release to complete 40 procedures across 9 hospitals, with strong positive physician feedback. Agile Devices has raised ~$3.8MM in investment capital and an additional ~$3.5MM in nondilutive grants.

Voice-of-the-customer (VOC) interviews with dozens of interventional radiologists have shown that the biggest problem with existing microcatheters is a lack of active tip control, which leads to increased procedure time, cost, and risk to patient outcomes.
Operators currently rely on torqueable guidewires to access the target vessels and then track the shaped or straight microcatheter over the wire to the target site. They often need to remove and either re-shape or replace the guidewire and/or microcatheter, especially in tortuous anatomy or when targeting multiple sites.

The Agile Devices Angler® deflectable microcatheter gives clinicians all the benefits of a standard microcatheter plus the added ability to actively deflect and steer the distal tip intraoperatively with or without a guide wire in place. This product was developed using Agile Devices’ quality system and using experienced regulatory and quality consultants.


  • Actively bi-directional deflectable and steerable tip, up to 180 degrees in each direction

  • Only requires one configuration and two lengths to allow for radial or femoral access – no need for multiple tip shapes

  • 0.021” I.D. for 0.018” guide wire compatibility, 3F Maximum O.D.

  • Excellent pushability, trackability, and torqueability

  • Delivers diverse agents (beads, glues etc.) just like any other microcatheter

The global microcatheter market was estimated to be roughly $800m in 2023, forecasted to grow to more than $1B by 2028 (BCC Research, M&M Research, Agile Devices estimates). The rapid growth of this market is primarily driven by the increasing global incidence of cardiovascular disease, an aging population, and the comprehensive shift to minimally invasive procedures over open surgery. The US, our beachhead geography, is estimated to represent roughly 40% of the global market.

The microcatheter space is consolidated, dominated by large medical device companies including Medtronic, Boston Scientific, J&J, and Stryker. Most models are largely undifferentiated, aside from materials, length, and tip shapes. Innovations have been made recently with other deflection technologies, but they are cost-prohibitive for most institutions and/or have functional deficiencies
limiting their commercial potential.

The Angler® has been shown to navigate to a wide range of anatomical targets faster than best-in-class conventional microcatheters (evidenced by bench/animal testing). This functional advantage holds the potential to reduce procedure time, cost, and risk, and increase hospital care capacity and revenue. Our core competitive edge is our coaxial deflection IP/technology that overcomes
limitations of pull-wire and other deflection technologies.

Agile Devices is targeting procedures requiring navigation to multiple targets, OR tortuous vessels in the neuro, coronary, and peripheral vasculature, representing 70%+ of this market, according to our extensive primary research with practicing interventional radiologists, cardiologists, and neuroradiologists. Customers include hospital purchasing teams, office-based lab management
teams, and ambulatory surgical center teams. Purchase decisions are made by committees consisting of administrative leadership and senior interventional physicians at each institution. The market consists of three main segments: neuro, coronary, and peripheral vascular.

Agile Devices has developed the Angler® Steerable and Deflectable Microcatheter cleared for peripheral and coronary vascular use in the US. As we develop further indications of our device and gain positive word-of-mouth validation from early adopter clinicians (through a small set of initial independent direct sales to hospital purchasing managers, aided by our clinical advisory network), we
will primarily look to partner with an established medical device company through a direct acquisition or structured acquisition pathway with milestones/triggers in place. To-date, we have built interest in our device primarily through leveraging our clinical advisors' vast network around the US for introductions and demonstrations. We focus on the value proposition that the device is
designed to reduce procedure time, cost, and risk. Our goal has always been to de-risk the technology from a clinical perspective (with early sales and a monitored launch) as we did from technical and regulatory perspectives, but not build out a formal commercial team prior to exit.


  • FDA clearance for peripheral and coronary vascular interventions (Q1, 2022)

  • Limited Market Evaluation (LME) of 40 procedures at 9 sites around US completed with strong positive physician feedback

  • Next-generation neuro-specific product (NeuroNavTM) nearing Design Select stage (est. Q2, 2024)

  • NeuroNav Design Freeze completed by end of year 2024

  • Significant inbound engagement with major medical device manufacturers interested in this technology

Agile Devices’ patent protected (US 9,233,225) tip deflection mechanism is based on an innovative coaxial design. Agile Devices has designed variable stiffness inner and outer shafts and an ergonomic handle to deflect the distal tip. This patented technology is scalable. Prototypes have been made with both smaller and larger inner and outer diameters. It is also a platform that can be translated for several non-vascular applications, such as GI, ENT, and others that may benefit from deflectable-tip devices.

The Agile Devices Angler® Steerable, Deflectable Microcatheter is intended for general intravascular use, including peripheral and coronary vasculature. Once the sub-selective region has been accessed, the microcatheter can be used for the controlled infusion of diagnostic agents and delivery of embolic or therapeutic devices. It is meant to be used only with contrast media and therapeutic
devices that have been cleared or approved for use in the intended target area.

Agile Devices’ patent protected (US 9,233,225) tip deflection mechanism is based on an innovative coaxial design. Agile Devices has designed variable stiffness inner and outer shafts and an ergonomic handle to deflect the distal tip. This patented technology is scalable. Prototypes have been made with both smaller and larger inner and outer diameters. It is also a platform that can be translated for several non-vascular applications, such as GI, ENT, and others that may benefit from deflectable-tip devices.

Inner and Outer Shafts: Both the inner and outer shafts of our coaxial design were designed with a variable stiffness profile (stiffer proximally and softer distally) for optimal pushability and trackability. The inner shaft has a consistent 0.021” I.D. from the luer to the tip to maximize flow and embolic delivery.

Ergonomic Handle: The handle was optimized to fit in the IR physician’s hand for constant single-handed use while allowing the other hand to manipulate a wire or other devices. With this intuitive design, the physician can easily deflect the tip in both directions and does not have to look away from the fluoroscopy screen while deflecting the tip and/or manipulating the wire.

Deflectable Tip Design: The fully covered 1.5cm tip is designed to deflect consistently up to 180 degrees in both directions (on a single plane). The distal and proximal marker bands allow physicians to see the deflection of the entire tip under fluoroscopy.


  • ~$1.15m target extension of Seed-2 financing

  • Preferred equity shares

  • $7.5m pre-money valuation, ~$10m post-money valuation (including ~$1.35m Seed-2 funds raised in Dec 2022)

  • All other terms remain unchanged from Seed-2 financing


Ben Merewitz: CEO, Co-Founder, Board Director – 15+ years of strategy, management consulting, product management, corporate development, and executive leadership experience across medtech, biopharma, and industrials. MIT Sloan MBA.
Stephen Hebert: Inventor, Co-Founder – 25+ years of medical device design and founder of 5 medical device companies; Started and sold 2 neurovascular device companies to Micrus / J&J including a pull wire deflectable microcatheter called Enzo.
Leo Tsai, MD PhD MSc: Co-Founder and Medical Lead; Radiologist, Mass General Hospital; Assistant Professor of Radiology, Harvard Medical School.
Stephen Tully: V.P. of R&D – 25+ years medical device R&D experience (USCI, Bard, Covidien, Terumo, Medtronic) – Most recently developed product portfolio for Beacon Endoscopic, ultimately sold to Covidien / Medtronic.
William Gorman: Regulatory & Quality Lead (consultant) – 35+ years medical device regulatory/quality/development experience. Has shepherded dozens of devices from concept to market.

Muneeb Ahmed, MD: Chief, Division of Vascular and Interventional Radiology, Beth Israel Deaconess Medical Center (BIDMC). Associate Professor of Radiology, Harvard Medical School.
Ammar Sarwar, MD: Co-Director of Liver Tumor Program, Beth Israel Deaconess Medical Center (BIDMC). Assistant Professor of Radiology, Harvard Medical School.
Ajit Puri, MD: Chief, Division of Interventional Neuroradiology, UMass Memorial Medical Center (UMMMC). Professor of Radiology, Neurosurgery and Neurology, UMMMC.
Anand S. Patel, MD: Chairman of Radiology, Providence Little Company of Mary Medical Centers - Torrance & San Pedro, CA; Research Associate of Radiology, UCSF Medical Center

Ben Merewitz: Board Chair; Bio above.
Christopher Rich: Board Director; Angel investor, member of Launchpad Venture Group and Sky Ventures; Corporate executive, advisor, and investor in global consumer healthcare; Led GlaxoSmithKline Consumer Healthcare’s $3 billion Wellness business; Extensive track record of marketing and new product leadership roles at Gillette / Procter & Gamble. A.B. in Economics/East Asian Studies from Harvard University and MBA from the Tuck School of Business at Dartmouth.
Patrick Rivelli: Board Director; Serial medical device entrepreneur, executive and investor for 25+ years. Currently CEO of SanaHeal, former CEO of SMART Therapeutics (acquired by Boston Scientific) & Bioabsorbable Therapeutics (acquired by Multi Cell Corporation). A.B. in Economics from Harvard University and MS in Management from the MIT Sloan School. Holds 9 issued patents.
Will Iselin: Board Observer/Advisor; Angel investor, member of Launchpad Venture Group. Experienced corporate executive, private company investor and corporate financier in the UK and the US, with decades of investment banking and transactional experience. Shareholder/director in many private companies. A.B. in History from Harvard University. 4-time US NCAA Squash Champion.
Stephen Tully: Board Observer/Advisor; Bio above.




20221117 Agile - Merewitz.jpg



Ben Merewitz brings over 15 years of experience launching and managing
businesses in industrials, biopharma and medical technology. Prior to Agile
Devices, Ben spent most of his career advising management teams and
launching products in high-tech sectors with heavy regulatory oversight. From
building and scaling the first solar inverter market research practice to
advising global publicly traded biopharma companies on multibillion dollar
decisions, Ben has consistently delivered strategic value to the C-suite, either
as an external consultant or an internal advisor or Chief of Staff. As an
operator, Ben has designed, built, and scaled products and services ranging
from aviation mobile applications to APAC-focused biotech consultancies,
consistently delivering 7+ figure revenue in the first year following launch.
Ben has excelled in emerging/midsize companies (PureSense, PHOTON
Consulting, Sentient Jet) and large multinational companies (Wellington
Management, Alexion Pharmaceuticals, DRG and Clarivate), with functional
responsibilities primarily in corporate development, product management, and
management consulting. Ben holds a BA in Psychology from Amherst College
and MBA in General Management from MIT Sloan.


20210614 MomiBaby logo cropped.jpg


Thursday, April 2, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Hal Eason, CEO of mōmi
Complimentary for HBS Angels Members


The revolutionary mōmi nipple works just like natural nursing, and is designed to reduce nipple confusion, bottle refusal and stress.


20240201 Nuvio Mobility.jpg


Thursday, February 1, 2024 9am PT, 12pm ET, 5pm London, 6pm Continental Europe

Presenter: Dr. Matt Cumella, Founder of Nuvio Mobility
Complimentary for HBS Angels Members


On behalf of the Boston chapter, we would like to share the following investment opportunity:

Why Nuvio?
Nuvio is empowering those with physical mobility challenges to move their best in their daily lives while supporting data-driven, connected care by developing the safest and smartest everyday mobility devices on the market. Nuvio is a member of AARP's distinguished AgeTech Collaborative and was founded by a Doctor of Physical Therapy. We’ve partnered with a world-class product engineering and design company to re-engineer walkers and address common challenges faced by users. Our innovative solutions are shaped by input from PTs, OTs, MDs, and consumers.

Globally, 200M people use walkers for limited mobility, and in the US, 46M adults face physical mobility difficulties. The aging and disability markets represent $8T in disposable income globally, with Baby Boomers and the Disability segment controlling more than 50% of the buying power in the US. The Global Walking Assist Devices market is expected to grow from $3.86B in 2021 to $6.51B by 2030, driven by the rising geriatric population and lifestyle changes. The demand for walking devices is attributed to the growing prevalence of chronic diseases, falls, arthritis, and sports-related injuries. The "Premium" walker segment, where Nuvio competes, is already 41% and the fastest growing segment due to a demand for greater quality and function. Competitors in this segment have improved quality and may incorporate identified benefits, such as using lightweight materials. Prices of walkers in this segment range from $650-$4000 based on functionality.

Current walkers represent a 40+ year status quo. They lack advanced data collection capabilities and fail to address common user complaints, presenting major opportunities for improvement to optimize mobility in critical ways that decrease falls, enhance recovery outcomes, and reduce burdens on caregivers.
Everyday mobility is an important indicator of health. Wearables aren’t designed for those with mobility issues, and mobility data is hard to collect for healthcare professionals using manually intensive existing methods. The result is a lack of insights and limited understanding and support for mobility challenges.


  • Hardware Innovations: With 6 patents pending, we’ve re-engineered the walker to address common complaints and improve mobility, like difficulty standing from a chair - by itself a leading cause of disability resulting in falls for 15M older adults in the US annually. Our walkers make it easier to get up, walk stably, sit, and complete reaching tasks, reducing the risk of falls.

  • Software Innovations: Nuvio Connect turns our walkers into a mobility assessment tool using IoT-onboard sensors. Unlike wearables, our walkers are designed to gather mobility insights tailored to individuals with mobility issues as recommended by PTs and MDs. From real-time actionable insights to predictive modeling, Nuvio Connect revolutionizes everyday mobility assessments with value propositions for multiple stakeholders. Unlike competitors, PTs and MDs generate revenue with our walkers through remote monitoring billing codes.

20240201 Nuvio - Images.jpg

Nuvio’s segment focus is B2B/B2B2C, with commercial traction that includes 3 signed distributor LOIs for our Base model, including a large national VA contractor, representing 3000+ units in future sales. We have several other sales partners throughout the US and Canada, including BestBuy Health. With customers in the pipeline across the US, Canada, Australia, and the EU, we are poised for significant market penetration and growth.

Business Model
Nuvio generates revenue through both per-unit sales and SaaS subscriptions. We will sell our walkers with and without Nuvio Connect. Our Base or hardware-only model will sell for $750 MSRP. Our Nuvio Connect model will sell for $1000 MSRP with a $15/mth/user subscription. The company projects 7000 units in Y1 sales / $4M in revenue and profitability by Q3 2025, growing to $119M in sales and a strong 86% operating margin in 2027.


The CEO/Founder and Inventor is a Doctor of Physical Therapy board-certified in Geriatrics with a passion for keeping people moving and independent. Our team has deep expertise in their verticals across operations, supply chain management, tech-enabled hardware product management, and marketing. We are partnered in investment with InertiaPD, a world-class Toronto-based product development firm. A subsidiary of Inertia, Inertia Manufacturing Services, are scale-up manufacturing experts who build market-ready products with uncompromising quality at scale. They have deep relationships with their manufacturers and vendors to launch products with quality and speed.

Financing History
2020 - Bootstrapping by Founder
2021 - $1M in a Simple Agreement For Future Equity(SAFE) at $5.5M post-money valuation cap, 20% discount from family, friends, and angel investors for development, team growth, and commercialization readiness


We are seeking up to $1.5M in seed funding for 24 months runway to achieve 1st-yr production and sales milestones of 7000 units. Funds will go toward production, team growth, marketing, and full development of our sensor/software package. We already have $1M committed and $500k in the bank.

Industry: Mobility Devices
Founded: May 2020
Pre-money Valuation: $6,500,000
Offering: Convertible Security
Capital Seeking: $1,500,000

Bill Popik, MD (Advisor/Investor), Martin Gavin (Advisor/Investor), Calypso Partners, HBS Boston, AIF, Inertia PD




20240201 Nuvio - Cumella.jpg



Dr. Matt Cumella is a Doctor of Physical Therapy who also holds a board
specialization in Geriatrics. Over 10 years in the field of Physical Therapy
with expertise related to complex injury and geriatric populations. Clinical
experience spans from Burn-Trauma ICU settings to geriatric outpatient,
with the vast majority of his career spent in inpatient rehab. He has
witnessed the transformative impact that the right assistive mobility tools
can have on patients’ success. However, everyday-use tools like walkers
haven’t kept up with institutional and hospital-based advancements in
technology and equipment – leaving users, caregivers, and providers
limited. Motivated by this gap, Dr. Cumella founded Nuvio to create the
safest and smartest everyday solutions on the market.


20240201 Nuvio Mobility
20231219 pente_logo
20221011 Moxie_Scrubs_Logo NEW_edited
20230727 Mercator logo
20230715 Fuego logo
20230323 Measure Studio logo hi-res 300X90
20230126 Avadain Logo tm
20210614 MomiBaby logo cropped
20221201 EarthGrid_COLOR 200X50
20221117 Agile Devices HIRES_edited
20221110 Epilogue Systems logo
20221011 Moxie_Scrubs_Logo NEW_edited
20220922 TANG app 400X210
20220908 Beckon-FullLogo 400X252
20220531 SurgiBox logo 200X133
20220523 Alleviate-Therapy 200X
20220425 egs-logo
20220413 Eunimart logo 300X
20220201 Lingrove
20210906 Moxie_Scrubs_Logo 500X135
20210819 Landsdowne Labs
20210722 RocketStar
20210614 MomiBaby logo cropped
20210527 Cognoptix logo 200X36
20210427 Synd Call LUPII_LOGO 200X
20210121 TANG app 2 150X
20201209 Wave logo 200X
20201203 Beckon logo
20200826 New View logo
20200811 BrightSpec Logo
Cargo Chief
Health Hero
Tire Agent


Use arrows on the side to navigate


A company must meet a threshold of member investment in one of our HBS Alumni Angel Chapters listed here. The leadership of the host chapter nominates the company for global syndication and provides a local member contact to act as syndication lead and a company contact.


Ideally, for global syndication a company should meet the following requirements:

  • Local host chapter members committed to invest at least $50,000* and local chapter forwards deal to global for syndication; 

  • Company assures at least $50,000-100,000 investible capacity;

  • Company provides at least 2 weeks for due diligence following the webinar, prior to requiring an investment decision;

  • Minimum individual investment amount is set at $25,000 or less;

  • Company agrees to a one-time admin fee of $1500.

The Global Syndication Committee selects the most suitable company candidates from the 15 participating HBSAA chapters and is aiming to host monthly webinars. 

*NY and other larger chapters may have a $100,000 min.

bottom of page